HTR2A is Associated with SSRI Response in Major Depressive Disorder in a Japanese Cohort
Tóm tắt
Several recent investigations reported that the serotonin 2A receptor gene (HTR2A) was associated with selective serotonin reuptake inhibitors (SSRIs) in major depressive disorder. There have also been two reported association analyses of HTR2A with SSRI response in Japanese MDD patients, but the results were rather inconsistent and both studies had the problem of small sample sizes. Therefore, we conducted a replication association study using a sample larger than those in the two original Japanese studies (265 MDD patients), and found that four SNPs, two functional SNPs (-A1438G: rs6311 and T102C: rs6313) and two SNPs (rs7997012 and rs1928040) in HTR2A, were associated with the therapeutic response to SSRIs. HTR2A was associated with the therapeutic response SSRIs in Japanese MDD patients in a haplotype-wise analysis (P
all markers = 0.0136), and a significant association between rs1928040 in HTR2A and SSRI response was detected in MDD (P
allele-wise analysis = 0.0252). However, this significance disappeared after Bonferroni correction (P
allele-wise analysis = 0.101). In conclusion, we suggest that HTR2A may play an important role in the pathophysiology of the therapeutic response to SSRIs in Japanese MDD patients. However, it will be important to replicate and confirm these findings in other independent studies using large samples.
Tài liệu tham khảo
Bowden, C. L. (2001). Strategies to reduce misdiagnosis of bipolar depression. Psychiatric Services, 52(1), 51–55.
Dudbridge, F. (2003). Pedigree disequilibrium tests for multilocus haplotypes. Genetic Epidemiology, 25(2), 115–121.
Kasper, S., Dotsch, M., Kick, H., Vieira, A., & Moller, H. J. (1993). Plasma concentrations of fluvoxamine and maprotiline in major depression: Implications on therapeutic efficacy and side effects. European Neuropsychopharmacology, 3(1), 13–21.
Kato, T. (2007). Molecular genetics of bipolar disorder and depression. Psychiatry and Clinical Neurosciences, 61(1), 3–19.
Kato, M., Fukuda, T., Wakeno, M., Fukuda, K., Okugawa, G., Ikenaga, Y., et al. (2006). Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology, 53(4), 186–195.
Kato, M., & Serretti, A. (2008). Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry (in press).
Kishi, T., Kitajima, T., Ikeda, M., Yamanouchi, Y., Kinoshita, Y., Kawashima, K., et al. (2009a). Association study of clock gene (CLOCK) and schizophrenia and mood disorders in the Japanese population. European Archives of Psychiatry and Clinical Neuroscience, 259(5), 293–297.
Kishi, T., Kitajima, T., Ikeda, M., Yamanouchi, Y., Kinoshita, Y., Kawashima, K., et al. (2009b). CLOCK may predict the response to fluvoxamine treatment in Japanese major depressive disorder patients. Neuromolecular Medicine, 11(2), 53–57.
Kishi, T., Kitajima, T., Ikeda, M., Yamanouchi, Y., Kinoshita, Y., Kawashima, K., et al. (2008). Association analysis of nuclear receptor Rev-erb alpha gene (NR1D1) with mood disorders in the Japanese population. Neuroscience Research, 62(4), 211–215.
Kishi, T., Kitajima, T., Tsunoka, T., Ikeda, M., Yamanouchi, Y., Kinoshita, Y., et al. (2009c). Genetic association analysis of serotonin 2A receptor gene (HTR2A) with bipolar disorder and major depressive disorder in the Japanese population. Neuroscience Research, 64(2), 231–234.
Kishi, T., Kitajima, T., Tsunoka, T., Okumura, T., Ikeda, M., Okochi, T., et al. (2009d). Possible association of prokineticin 2 receptor gene (PROKR2) with mood disorders in the Japanese population. Neuromolecular Medicine, 11(2), 114–122.
McMahon, F. J., Buervenich, S., Charney, D., Lipsky, R., Rush, A. J., Wilson, A. F., et al. (2006). Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. American Journal of Human Genetics, 78(5), 804–814.
Myers, R. L., Airey, D. C., Manier, D. H., Shelton, R. C., & Sanders-Bush, E. (2007). Polymorphisms in the regulatory region of the human serotonin 5-HT2A receptor gene (HTR2A) influence gene expression. Biological Psychiatry, 61(2), 167–173.
Perlis, R. H., Fijal, B., Adams, D. H., Sutton, V. K., Trivedi, M. H., & Houston, J. P. (2009). Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biological Psychiatry, 65(9), 785–791.
Peters, E. J., Slager, S. L., Jenkins, G. D., Reinalda, M. S., Garriock, H. A., Shyn, S. I., et al. (2009). Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. Pharmacogenet Genomics, 19(1), 1–10.
Peveler, R., & Kendrick, T. (2005). Selective serotonin reuptake inhibitors: THREAD trial may show way forward. British Medical Journal, 330(7488), 420–421.
Purcell, S., Cherny, S. S., & Sham, P. C. (2003). Genetic power calculator: Design of linkage and association genetic mapping studies of complex traits. Bioinformatics, 19(1), 149–150.
Saito, S., Takahashi, N., Ishihara, R., Ikeda, M., Suzuki, T., Kitajima, T., et al. (2006). Association study between vesicle-associated membrane protein 2 gene polymorphisms and fluvoxamine response in Japanese major depressive patients. Neuropsychobiology, 54(4), 226–230.
Sato, K., Yoshida, K., Takahashi, H., Ito, K., Kamata, M., Higuchi, H., et al. (2002). Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder. Neuropsychobiology, 46(3), 136–140.
Serretti, A., & Artioli, P. (2004a). From molecular biology to pharmacogenetics: A review of the literature on antidepressant treatment and suggestions of possible candidate genes. Psychopharmacology (Berl), 174(4), 490–503.
Serretti, A., & Artioli, P. (2004b). The pharmacogenomics of selective serotonin reuptake inhibitors. The Pharmacogenomics Journal, 4(4), 233–244.
Serretti, A., Calati, R., Giegling, I., Hartmann, A. M., Moller, H. J., Colombo, C., et al. (2007a). 5-HT2A SNPs and the Temperament and Character Inventory. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 31(6), 1275–1281.
Serretti, A., Drago, A., & De Ronchi, D. (2007b). HTR2A gene variants and psychiatric disorders: A review of current literature and selection of SNPs for future studies. Current Medicinal Chemistry, 14(19), 2053–2069.
Serretti, A., & Mandelli, L. (2008). The genetics of bipolar disorder: Genome ‘hot regions’, genes, new potential candidates and future directions. Molecular Psychiatry, 13(8), 742–771.
Spurlock, G., Heils, A., Holmans, P., Williams, J., D’Souza, U. M., Cardno, A., et al. (1998). A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. Molecular Psychiatry, 3(1), 42–49.
Stensland, M. D., Schultz, J. F., & Frytak, J. R. (2008). Diagnosis of unipolar depression following initial identification of bipolar disorder: A common and costly misdiagnosis. Journal of Clinical Psychiatry, 69(5), 749–758.
Wilkie, M. J., Smith, G., Day, R. K., Matthews, K., Smith, D., Blackwood, D., et al. (2008). Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. The Pharmacogenomics Journal.
Williams, J. B. (1988). A structured interview guide for the Hamilton Depression Rating Scale. Archives of General Psychiatry, 45(8), 742–747.